Meta-analysis of tripterygium glycosides combined with methotrexate in the treatment of rheumatoid arthritis

doi:10.3969/j.issn.2095-4344.1431

Abstract

Abstract:

BACKGROUND: The efficacy of tripterygium glycosides is equal to the methotrexate in the treatment of rheumatoid arthritis, and the clinical efficacy of the combination of tripterygium glycosides and methotrexate is better.
OBJECTIVE: To systematically evaluate the efficacy of tripterygium glycosides combined with methotrexate in the treatment of rheumatoid arthritis, so as to provide evidence-based reference for clinical practice.
METHODS: PubMed, The Cochrane Library, CNKI, WanFang and SinoMed databases were searched from database establishment time to December 31, 2018. The clinical trial data of tripterygium glycosides combined with methotrexate (trial group) and methotrexate (control group) in the treatment of rheumatoid arthritis were collected. The Cochrane system was used to evaluate the quality of the literature. RevMan 5.3 software was used to conduct a meta-analysis of the overall effects of 10 studies.
RESULTS AND CONCLUSION: (1) Meta-analysis results showed that: morning stiffness [SMD=−1.51, 95%CI (-2.31, −0.71), P=0.000 2], joint swollen and pain [SMD=−1.50, 95%CI (-2.66, −0.35), P=0.001], joint pressure pain [SMD=−1.28, 95%CI (-1.98, −0.57), P=0.000 4], joint swelling [SMD=−1.46, 95%CI (-2.48, −0.44), P=0.005], erythorcyte sedimentation rate [SMD=−1.86, 95%CI (-2.90, −0.83), P=0.000 4], C-reactive protein [SMD=−1.50, 95%CI (-2.40, −0.60), P=0.001], rheumatoid factor [SMD=−1.11, 95%CI (-1.96, −0.26), P=0.01], and incidence of adverse reaction [RR=0.67, 95%CI (0.48, 0.93), P=0.002] in the trial group was significantly lower than that in the control group. (2) The total effective rate in the trial group was significantly better than that in the control group [RR=1.23, 95%CI (1.13, 1.35), P < 0.000 01]. (3) These results indicate that tripterygium glycosides combined with methotrexate in the treatment of rheumatoid arthritis can elevate the efficiency, improve the various signs and symptoms associated with rheumatoid arthritis, reduce the side effects of drugs, and have good safety.

Key words: tripterygium glycosides, methotrexate, rheumatoid arthritis, morning stiffness, erythorcyte sedimentation rate, C-reactive protein, rheumatoid factor, meta-analysis

CLC Number:

Yin Cong, Chen Xin, Sun Hui, Yu Axiang, Yuan Lijun, Tong Zhibin, Cheng Yinjie, Tu Xing. Meta-analysis of tripterygium glycosides combined with methotrexate in the treatment of rheumatoid arthritis[J]. Chinese Journal of Tissue Engineering Research, 2019, 23(35): 5710-5717.

Figures/Tables 7

References

[1]Picerno V, Ferro F, AdinolfiA,etal.One year in review: the pathogenesis of rheumatoid arthritis. ClinExpRheumatol. 2015;33(4):551.

[2]Gao Q, Wang YX, Xu D, et al. Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies. Bone Res.2018;(6): 15.

[3]池里群,周彬,高文远,等.治疗类风湿性关节炎常用药物的研究进展[J].中国中药杂志, 2014,39(15):2851-2858.

[4]昊霞,林兵,王忠震,等.雷公藤的免疫抑制活性及毒性的谱效关系研究[J].中国医院药学杂志,2016,36(7):547-552.

[5]黄晶,舒晓明,王贵,等.甲氨蝶呤治疗类风湿关节炎的作用机制[J].中华临床医师杂志(电子版),2016,10(21):3276-3280.

[6]杨冬梅,刘俊.雷公藤多苷临床应用及不良反应的研究进展[J].中国医院药学杂志,2018,38(20):2185-2190.

[7]王娟芳.雷公藤治疗类风湿性关节炎的疗效观察[J].内蒙古中医药,2017,36(04):31.

[8]Lv QW, Zhang W, Shi Q, et al. Comparison of Tripterygiumwilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA) :a randomized, controlled clinical trial.Ann Rheum Dis.2015; 74(6):1078-1086.

[9]吴琼.门急诊超适应证处方调查及其对策[J].中医药管理杂志, 2018,26(20):24-26.

[10]张晓攀,李艳贞,李珊珊,等.类风湿性关节炎治疗药物研究进展[J].药物评价研究,2018,41(10):1906-1910.

[11]Saag KG, Teng GG, Patkar NM, et al.American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.Arthritis Rheum.2008; 59(6): 762-784.

[12]Smolen JS, Lendewe R, Breedveld FC, et al.EULAR rec-ommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying anti-rheu-matic drugs.Ann Rheum Dis.2010;69(6):964-975.

[13]郑筱萸.中药新药临床研究指导原则(试行)[S].北京:中国医药科技出版社,2002:115.

[14]吕芳,李兴福.2010年美国风湿病学会联合欧洲抗风湿病联盟的类风湿关节炎分类标准解[J].诊断学理论与实践, 2010,9(4): 307-310.

[15]郑明华.Meta分析软件应用与实例解析[M].北京:人民卫生出版社,2013.

[16]朱琳,陈鹏.甲氨蝶呤联合雷公藤多苷与单用甲氨蝶呤治疗类风湿关节炎效果比较[J].检验医学与临床, 2015,12(23): 3568-3570.

[17]杨敏,周润华,李宝贞,等.甲氨蝶呤联合雷公藤多苷治疗老年类风湿关节炎[J].中国实验方剂学杂志,2013,19(17):300-304.

[18]陈曾凤,兰培敏,陈汉玉,等.雷公藤多苷联合甲氨蝶呤治疗类风湿关节炎活动期患者的疗效及对血清CD62p?CD41的影响[J].现代生物医学进展,2018,18(20):3909-3912+3921.

[19]毕丹艳,李芹,张虹,等.雷公藤多苷联合甲氨蝶呤治疗类风湿关节炎的临床疗效研究[J].中国临床药理学杂志, 2016,32(10): 880-882.

[20]周红.雷公藤多苷与甲氨蝶呤联合治疗类风湿关节炎的疗效分析[J].中国医药指南,2017,15(06):191.

[21]高鹏,霍爱鑫,刘宇宏.雷公藤多苷联合甲氨蝶呤治疗类风湿性关节炎的疗效[J].西部医学,2017,29(11):1511-1515.

[22]袁毅.雷公藤多苷联合甲氨蝶呤治疗类风湿关节炎效果观察[J].临床医学,2018,38(1):100-101.

[23]沈杰.雷公藤多苷联合小剂量甲氨蝶呤治疗老年性类风湿关节炎临床观察//中国中西医结合学会皮肤性病专业委员会.第四次全国雷公藤学术会议论文汇编[C].中国中西医结合学会皮肤性病专业委员会:中国中西医结合学会,2004.

[24]王海波,崔永虹,刘杰.雷公藤多苷片联合甲氨蝶呤片治疗类风湿性关节炎临床分析[J].临床合理用药杂志,2016,9(35):52-53.

[25]赵伟伟.评价雷公藤多苷联合甲氨蝶呤治疗类风湿关节炎的疗效及安全性[J].首都食品与医药,2018,25(22):38.

[26]尹聪,陈鑫,涂星,等.灯盏细辛注射液不良反应的Meta分析[J].中国民族民间医药,2018,27(15):47-54.

[27]李淼,刘志丹,赵创,等.类风湿关节炎相关microRNA 研究进展[J].国际免疫学杂志,2017,40(4): 429-434.

[28]Louthernoo W, Nilganuwong S, Nanagara R, et al. THU0207 Diacere in Combination with Methotrexate versus Methotrexate Alone in The Treatment of Early Rheumatoid Arthritis.2016;75(2):262.

[29]Mirzaei A, Ataeipoor Y, Asgari M, et al. Seropositivity of Rheumatoid Arthritis Specific Tests in a Patient With Nephrotic Syndrome: Successful Treatment With Rituximab. Iran J Kidney Dis.2017;11(6):467-468.

[30]Aota Y, Nonaka T, Kimura S, et al. A methotrexate-associated Lympholiferative disorder patient with gastrointestinal perforation.Nihon Ronen Igakkai Zasshi.2017; 54(4): 567-572

[31]Papachristou M, Kastis GA, Stavrou PZ, et al. Radiolabeled methotrexate as a diagnostic agent of inflammatory target sites: A proof-of-concept study. Mol Med Rep.2018;17(2): 2442-2448.

[32]杨敏,周润华,李宝贞,等.甲氨蝶呤联合雷公藤多苷治疗老年类风湿关节炎[J].中国实验方剂学杂志,2013,19(17) : 300-304.

[33]Li H, Guo F, Luo YC, et al. Efficacy of tripterygium glycosides tablet in treating ankylosing spondylitis: a systematic review and meta-analysis of randomized controlled trials. Clin Rheumatol.2015; 34(11): 1831-1838.

[34]陈秀敏,黄闰月,晏菁遥,等.化瘀通痹方联合甲氨蝶呤治疗难治性类风湿关节炎临床观察[J].中国中西医结合杂志, 2015,35(11): 1326-1330.